Gene copy number and protein expression level [23] also showed some potential for use as biomarkers for EGFr tyrosine kinase inhibitors in lung cancer, but never gained the level of usage of EGFr mutation analysis, as was the case for Her2 in breast cancer clinical management and the use of Her2 targeted therapies. This evidence concerns the gene EGFR and breast carcinoma.